An observational study in Peripheral Neuropathy, Neuro-Degenerative Disease and Neuromuscular Diseases, sponsored by Elpida Therapeutics SPC. Active, not recruiting at 3 sites in United States. Per ClinicalTrials.gov, last updated 2026-07-08.
Sponsored by Elpida Therapeutics SPC · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 191 studies in Peripheral Nervous System Diseases with a site in United States — 31 open to participants now, 48 under way, 2 of them phase 3. Peripheral Nervous System Diseases · United States.
Among the 191 studies in Peripheral Nervous System Diseases with a site in United States, this one is the 25th largest by planned enrollment of the 31 observational ones that give a count, is one of 5 that started in 2024, is one of 31 observational ones, reaches primary completion later than 46 of the 46 other live ones, and was the 168th registered.
476 studies on the registry are indexed under Peripheral Nervous System Diseases; 103 are open to participants now.
Browse Peripheral Nervous System Diseases studies →31 of the 191 studies in Peripheral Nervous System Diseases with a site in United States are open now. Recruiting first, the newest first:
Dana-Farber Cancer Institute · Sites in United States
Ages 18+
Montefiore Medical Center · Sites in United States
Ages 18+
RxFunction Inc. · Sites in United States
Ages 60+
Yale University · Sites in United States
Ages 18+
Generate Biomedicines · Sites in United States
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 65 Peripheral Nervous System Diseases studies recruiting now, 44 (68%) set no upper age limit and 10 (15%) stop at 75 or younger; 8 take children under 18; 10 take healthy volunteers.
This study: all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
191 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 11 · Phase 2 40 · Phase 3 22 · Phase 4 4
First in 1984; this study’s year is marked. 5 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 20 is below the median of 80 across 97 observational studies indexed under Peripheral Nervous System Diseases.
Median enrollment 43 across the 157 interventional studies, 80 across the 31 observational. Of the 129 that completed or were terminated, 58 (45%) have results posted.
This tab as a report to print or save as PDF → With an account.
46 of 191 have an industry lead sponsor. The 10 most frequent:
Elpida Therapeutics SPC is the lead sponsor of 4 studies on the registry; 3 are open to participants now.
Elpida Therapeutics SPC has 1 study filed under Peripheral Nervous System Diseases — fewer than ten, so there is no comparison to draw.
21 of the studies in Peripheral Nervous System Diseases with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06848348Dogwood Therapeutics Inc.Efficacy and Safety Study of Halneuron in the Treatment of Chemotherapy-Induced Neuropathic Pain | 2026-12 |
| NCT04865679Axogen CorporationTolerability and Feasibility Pilot Clinical Study of a Large-Diameter Nerve Cap for Protecting and Preserving Terminated Nerve Ends | 2026-12 |
| NCT07674420Johns Hopkins UniversityWearable Insoles for Recurrent Diabetic Ulcer Prevention | 2027-01 |
| NCT04800484University of IowaThe Effects of AFO Heel Height and Stiffness on Gait | 2027-01-01 |
| NCT03584022Mayo ClinicClinical Trial to Assess the Safety of a Novel Scaffold Biomaterial | 2027-03 |
Add all 21 to your calendar (.ics) → With an account.
Among the 191 studies in Peripheral Nervous System Diseases with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a multicenter, longitudinal, prospective observational natural history study of subjects with a molecularly confirmed diagnosis of CMT4J. The study will enroll 20 subjects of any age into a uniform protocol for follow-up and evaluations. Subject visits will occur every 12 months + 4 weeks for up to 2 years.
This is a multicenter, longitudinal, prospective observational natural history study of subjects with a molecularly confirmed diagnosis of CMT4J. The study will enroll 20 subjects of any age into a uniform protocol for follow-up and evaluations. The study will obtain demographic and medical history information. Natural history data will be collected prospectively on an annual basis and may include physical/neurological exams, standard laboratory tests, CMT outcome and disability measures, neuropsychological tests, nerve conduction studies (NCS), and imaging studies (muscle MRI). Pulmonary function test (PFT) and scoliosis series x-ray Subject visits will occur every 12 months + 4 weeks for up to 2 years. Subjects who terminate from the study prior to Visit 3 will undergo an early termination/end of study visit (EOS) if possible. The early termination/end of study visit is comprised of the Visit 3 assessments. If needed, the Investigator may conduct unscheduled visits with Sponsor's approval. No investigational product will be used during the study.
Subjects with a genetically confirmed diagnosis of CMT4J will be included.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Study objective
This study is designed to investigate the clinical characteristics and natural history of CMT4J.
Time frame: 2 years
Plan to share: Yes — De-identified data for publication.
Supporting information: Study protocol, Informed consent form, Clinical study report
Time frame: Starting in January 2025
Access criteria: All Investigators leading the trial.
Started Jul 2024 (actual). Primary completion is estimated for Mar 2031, 79 months after the start.
Of 38 observational studies under Peripheral Nervous System Diseases, half reached primary completion within 43 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 93. This study's planned 79 months is above that.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Peripheral Nervous System Diseases →
Elpida Therapeutics SPC